The compelling clinical activity, durable response and acceptable tolerability profile seen with elironrasib underscore the potential of this differentiated RAS (ON) G12C-selective inhibitor, ...

The glomerulonephritis market is witnessing steady growth driven by the increasing prevalence of chronic kidney diseases and improved diagnostic ...

Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...

Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced new real-world preliminary data from the OPTION-VMS Phase IV, longitudinal, observational study, ...

Oilfield stimulation chemicals are vital for enhancing the recovery efficiency of hydrocarbons from reservoirs that have ...